PASD1 is a potential multiple myeloma–associated antigen

Immunotherapy is an important treatment option in multiple myeloma (MM), with allotransplantation demonstrating an inducible graft-versus-myeloma effect.[1][1] This could be potentiated by vaccination, first requiring knowledge of tumor-associated antigens. The cancer testis antigens (CTAs) are